FDA
-
-
-
-
-
-
-
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
-
-
-
-
-
-
-
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
-
-
-
-
-
-
-
PharmaTher receives FDA approval for ketamine product KETARx
-
-
-
-
-
-
-
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
-
-
-
-
-
-
-
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
-
-
-
-
-
-
-
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
-
-
-
-
-
-
-
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
-
323,752 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

